LENSAR, Inc. (LNSR) Q1 2024 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Lensar, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:04.597 proud of what we've accomplished to date, and I believe this is the start of a strong 00:00:04.597 -- 00:00:08.001 quarterly growth in placements and procedure revenue. 00:00:08.001 -- 00:00:11.185 Heretofore, Ally has only been marketed in the U.S. 00:00:11.185 -- 00:00:14.510 as we await additional regulatory approvals. 00:00:14.510 -- 00:00:19.917 Despite selling into a single market, Lensar has been able to achieve strong top-line 00:00:19.917 -- 00:00:24.262 growth and gain significant market share based on the compelling value proposition of 00:00:24.262 -- 00:00:25.664 Ally. 00:00:25.664 -- 00:00:30.171 U.S. sales pipeline activity and system utilization have steadily increased, and we look 00:00:30.171 -- 00:00:33.836 forward to offering Ally in other markets, especially Europe. 00:00:33.836 -- 00:00:39.282 Although Ally is not widely available outside the US, surgeons in Europe, South Korea, 00:00:39.282 -- 00:00:44.007 Taiwan, and Hong Kong are awaiting regulatory clearance and commercial availability in 00:00:44.007 -- 00:00:48.372 their home countries, and our distributors are preparing to make Ally available quickly 00:00:48.372 -- 00:00:51.735 after receipt of marketing authorizations. 00:00:51.735 -- 00:00:56.638 We expect additional regulatory clearances before the end of 2024. 00:00:56.821 -- 00:01:02.240 At the recent ASCRS annual meeting in Boston, We had our highest level of surgeon engagement 00:01:02.240 -- 00:01:06.785 in the company's history, completing nearly 100 Ally demos. 00:01:06.785 -- 00:01:11.511 In the femtosecond laser cataract session, eight of nine presentations were from Lensar 00:01:11.511 -- 00:01:16.536 surgeons, including one which was voted best presentation of the session. 00:01:16.536 --...